XNK Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Liquidation
XNK Therapeutics General Information
Description
Operator of a clinical-stage biotechnology company intended to prevent and treat cancer in patients. The company's platform created novel autologous natural killer cell cell-based therapies developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable, enabling medical professionals to focus their efforts to constitute key components in cancer treatments.
Contact Information
Website
www.xnktherapeutics.comCorporate Office
- Hälsovägen 7
- Novum
- 141 57 Huddinge
- Sweden
Corporate Office
- Hälsovägen 7
- Novum
- 141 57 Huddinge
- Sweden
XNK Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Bankruptcy: Liquidation | 09-Apr-2024 | Completed | Bankruptcy: Liquidation | |||
| 3. Later Stage VC | 29-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 12-Apr-2021 | $7.44M | $7.44M | Completed | Pre-Clinical Trials | |
| 1. Grant | 22-Nov-2018 | $110K | Completed | Pre-Clinical Trials |
XNK Therapeutics Comparisons
Industry
Financing
Details
XNK Therapeutics Competitors (1)
One of XNK Therapeutics’s competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Autolus | Formerly VC-backed | London, United Kingdom |
XNK Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
XNK Therapeutics Patents
XNK Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202115389-D0 | Methods | Inactive | 26-Oct-2021 | ||
| EP-4423246-A1 | Methods for expanding natural killer cells (nk cells) | Pending | 26-Oct-2021 | ||
| US-20250313804-A1 | Methods for expanding natural killer cells (nk cells) | Pending | 26-Oct-2021 | ||
| WO-2023072813-A1 | Methods for expanding natural killer cells (nk cells) | Inactive | 26-Oct-2021 | ||
| JP-2022522914-A | Medical use | Pending | 30-Apr-2018 | A61K35/17 |
XNK Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
XNK Therapeutics FAQs
-
When was XNK Therapeutics founded?
XNK Therapeutics was founded in 2012.
-
Where is XNK Therapeutics headquartered?
XNK Therapeutics is headquartered in Huddinge, Sweden.
-
What is the size of XNK Therapeutics?
XNK Therapeutics has 35 total employees.
-
What industry is XNK Therapeutics in?
XNK Therapeutics’s primary industry is Biotechnology.
-
Is XNK Therapeutics a private or public company?
XNK Therapeutics is a Private company.
-
What is XNK Therapeutics’s current revenue?
The current revenue for XNK Therapeutics is .
-
How much funding has XNK Therapeutics raised over time?
XNK Therapeutics has raised $21.2M.
-
Who are XNK Therapeutics’s competitors?
Autolus is a competitor of XNK Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
